高卫峰①, 李会晨②. 直肠癌新辅助放化疗临床效果的评估[J]. 中国肿瘤临床, 2015, 42(6): 360-362. DOI: 10.3969/j.issn.1000-8179.20150083
引用本文: 高卫峰①, 李会晨②. 直肠癌新辅助放化疗临床效果的评估[J]. 中国肿瘤临床, 2015, 42(6): 360-362. DOI: 10.3969/j.issn.1000-8179.20150083
Weifeng GAO1, Huichen LI2. Clinical evaluation of rectal cancer after neoadjuvant chemoradiotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 42(6): 360-362. DOI: 10.3969/j.issn.1000-8179.20150083
Citation: Weifeng GAO1, Huichen LI2. Clinical evaluation of rectal cancer after neoadjuvant chemoradiotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 42(6): 360-362. DOI: 10.3969/j.issn.1000-8179.20150083

直肠癌新辅助放化疗临床效果的评估

Clinical evaluation of rectal cancer after neoadjuvant chemoradiotherapy

  • 摘要: 直肠癌是常见的恶性肿瘤,直肠癌发病率近年有上升趋势。全直肠系膜切除术(total mesorectal excision ,TME )是直肠癌的最主要治疗手段,但局部进展期直肠癌患者术后局部复发率高、保肛率低,新辅助放化疗成为局部晚期直肠癌的优选治疗手段。直肠癌新辅助治疗后的临床效果是临床医生关注的焦点。直肠癌新辅助治疗效果的预测及评估关系到后续治疗方案的选择,影响患者的生存期及生活质量。

     

    Abstract: Rectal cancer is a common type of malignant tumor, with increasing incidence over the previous years. Total mesorec-tal excision is the most important treatment for rectal cancer. Advanced rectal cancer presents high local recurrence rate and low sphinc -ter preservation rate. For locally advanced rectal cancer, neoadjuvant chemoradiotherapy is the optimal management strategy. In this re -gard, clinicians have focused on investigating the clinical effects of rectal cancer after neoadjuvant chemoradiotherapy. Prediction and evaluation of rectal cancer after neoadjuvant therapy can be used to determine further necessary treatments, effect on quality of life, and survival time of patients.

     

/

返回文章
返回